Restricted accessResearch articleFirst published online 2018-11
The Neuroprotective Effect of Ethanol Intoxication in Traumatic Brain Injury Is Associated with the Suppression of ErbB Signaling in Parvalbumin-Positive Interneurons
Ethanol intoxication (EI) is a frequent comorbidity of traumatic brain injury (TBI), but the impact of EI on TBI pathogenic cascades and prognosis is unclear. Although clinical evidence suggests that EI may have neuroprotective effects, experimental support is, to date, inconclusive. We aimed at elucidating the impact of EI on TBI-associated neurological deficits, signaling pathways, and pathogenic cascades in order to identify new modifiers of TBI pathophysiology. We have shown that ethanol administration (5 g/kg) before trauma enhances behavioral recovery in a weight-drop TBI model. Neuronal survival in the injured somatosensory cortex was also enhanced by EI. We have used phospho–receptor tyrosine kinase (RTK) arrays to screen the impact of ethanol on TBI-induced activation of RTK in somatosensory cortex, identifying ErbB2/ErbB3 among the RTKs activated by TBI and suppressed by ethanol. Phosphorylation of ErbB2/3/4 RTKs were upregulated in vGlut2+ excitatory synapses in the injured cortex, including excitatory synapses located on parvalbumin (PV)-positive interneurons. Administration of selective ErbB inhibitors was able to recapitulate, to a significant extent, the neuroprotective effects of ethanol both in sensorimotor performance and structural integrity. Further, suppression of PV interneurons in somatosensory cortex before TBI, by engineered receptors with orthogonal pharmacology, could mimic the beneficial effects of ErbB inhibitors. Thus, we have shown that EI interferes with TBI-induced pathogenic cascades at multiple levels, with one prominent pathway, involving ErbB-dependent modulation of PV interneurons.
Get full access to this article
View all access options for this article.
References
1.
CoronadoV.G., XuL., BasavarajuS.V., McGuireL.C., WaldM.M., FaulM.D., GuzmanB.R., and HemphillJ.D.; Centers for Disease Control and Prevention (CDC). (2011). Surveillance for traumatic brain injury-related deaths—United States, 1997-2007. MMWR Surveill. Summ., 60, 1–32.
2.
BrunsJ., and HauserW.A. (2003). The epidemiology of traumatic brain injury: a review. Epilepsia, 44, Suppl. 10, 2–10.
3.
LeoP, and McCreaM. (2016). Epidemiology, in: Translational Research in Traumatic Brain Injury. D. Laskowitz and G. Grant (eds). CRC Press/Taylor and Francis Group: Boca Raton, FL, chapter 1.
4.
ZaloshnjaE., MillerT., LangloisJ.A., and SelassieA. W. (2005). Prevalence of long-term disability from traumatic brain injury in the civilian population of the United States. J. Head Trauma Rehabil., 23, 394–400.
5.
SteinC.S., GeorgoffP., MeghanS., MizraK., and SonnadS.S. (2010). 150 years of treating severe traumatic brain injury: a systematic review of progress in mortality. J. Neurotrauma, 27, 1343–1353.
6.
SavolaO., NiemeläO., and HillbomM. (2005). Alcohol intake and the pattern of trauma in young adults and working aged people admitted after trauma. Alcohol Alcohol, 40, 269–273.
7.
BrennanJ.H., BernardS., CameronP.A., RosenfeldJ.V., and MitraB. (2015). Ethanol and isolated traumatic brain injury. J. Clin. Neurosci., 22, 1375–1381.
8.
RajR., SkrifvarsM.B., KivisaariR., HernesniemiJ., LappalainenJ., and SiironenJ. (2015). Acute alcohol intoxication and long-term outcome in patients with traumatic brain injury. J. Neurotrauma, 32, 95–100.
9.
RajR., MikkonenE.D., SiironenJ., HernesniemiJ., LappalainenJ., and SkrifvarsM.B. (2016). Alcohol and mortality after moderate to severe traumatic brain injury: a meta-analysis of observational studies. J. Neurosurg., 124, 1684–1692.
10.
BerryC., LeyE.J., MarguliesD.R., MirochaJ., BukurM., MalinoskiD., and SalimA. (2011). Correlating the blood alcohol concentration with outcome after traumatic brain injury: too much is not a bad thing. Am. Surg., 77, 1416–1419.
11.
SalimA., TeixeiraP., LeyE.J., DuBoseJ., InabaK., and MarguliesD.R. (2009). Serum ethanol levels: predictor of survival after severe traumatic brain injury. J. Trauma, 67, 697–703.
12.
WangT., ChouD.Y., DingJ.Y., FredricksonV., PengC., SchaferS., GuthikondaM., KreipkeC., RafolsJ.A., and DingY. (2013). Reduction of brain edema and expression of aquaporins with acute ethanol treatment after traumatic brain injury. J. Neurosurg., 118, 390–396.
13.
JosephB., KhalilM., PanditV., KulvatunyouN., ZangbarB., O'KeeffeT., AsifA., TangA., GreenD.J., GriesL., FrieseR.S., and RheeP. (2015). Adverse effects of admission blood alcohol on long-term cognitive function in patients with traumatic brain injury. J. Trauma Acute Care Surg., 78, 403–408.
14.
PanditV., PatelN., RheeP., KulvatunyouN., AzizH., GreenD.J., O'KeeffeT., ZangbarB., TangA., GriesL., FrieseR.S., and JosephB. (2014). Effect of alcohol in traumatic brain injury: is it really protective?. J. Surg. Res., 190, 634–639.
15.
LangeR.T., IversonG.L., and FranzenM.D. (2008). Effects of day-of-injury alcohol intoxication on neuropsychological outcome in the acute recovery period following traumatic brain injury. Arch. Clin. Neuropsychol., 23, 809–822.
16.
SchutteC., and HanksR. (2010). Impact of the presence of alcohol at the time of injury on acute and one-year cognitive and functional recovery after traumatic brain injury. Int. J. Neurosci., 120, 551–556.
17.
KaplanC.P., and CorriganJ.D. (1992). Effect of blood alcohol level on recovery from severe closed head injury. Brain Inj. 6, 337–349.
18.
WuW., TianR., HaoS., XuF., MaoX., and LiuB. (2014). A pre-injury high ethanol intake in rats promotes brain edema following traumatic brain injury. Br. J. Neurosurg., 28, 739–745.
19.
VaagenesI.C., TsaiS.Y., TonS.T., HusakV.A., McGuireS.O., O'BrienT.E., and KartjeG.L. (2015). Binge ethanol prior to traumatic brain injury worsens sensorimotor functional recovery in rats. PloS One, 10, e0120356.
20.
ChandrasekarA., HeuvelF.O., PalmerA., LinkusB., LudolphA.C., BoeckersT.M., ReljaB., Huber-LangM., and RoselliF. (2017). Acute ethanol administration results in a protective cytokine and neuroinflammatory profile in traumatic brain injury. Int. Immunopharmacol., 51, 66–75.
21.
KellyD.F., LeeS.M., PinanongP.A., and HovdaD.A. (1997). Paradoxical effects of acute ethanolism in experimental brain injury. J. Neurosurg., 86, 876–882.
22.
JanisL.S., HoaneM.R., CondeD., FulopZ., and SteinD.G. (1998). Acute ethanol administration reduces the cognitive deficits associated with traumatic brain injury in rats. J. Neurotrauma, 15, 105–115.
23.
GoodmanM.D., MakleyA.T., CampionE.M., FriendL.A., LentschA.B., and PrittsT.A. (2013). Preinjury alcohol exposure attenuates the neuroinflammatory response to traumatic brain injury. J. Surg. Res., 184, 1053–1058.
24.
KatadaR., NishitaniY., HonmouO., MizuoK., OkazakiS., TatedaK., WatanabeS., and MatsumotoH. (2012). Expression of aquaporin-4 augments cytotoxic brain edema after traumatic brain injury during acute ethanol exposure. Am. J. Pathol., 180, 17–23.
25.
CriswellH.E., MingZ., PleasantN., GriffithB.L., MuellerR.A., and BreeseG.R. (2004). Macrokinetic analysis of blockade of NMDA-gated currents by substituted alcohols, alkanes and ethers. Brain Res. 1015, 107–113.
26.
KumarS., PorcuP., WernerD.F., MatthewsD.B., Diaz-GranadosJ.L., HelfandR.S., and MorrowA.L. (2009). The role of GABA(A) receptors in the acute and chronic effects of ethanol: a decade of progress. Psychopharmacology (Berl.) 205, 529–564.
MeiL., and NaveK.A. (2014). Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases. Neuron, 83, 27–49.
29.
GuptaV.K., YouY., GuptaV.B., KlistornerA., and GrahamS.L. (2013). TrkB receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders. Int. J. Mol. Sci., 14, 10122–10142.
30.
FourgeaudL., TravésP.G., TufailY., Leal-BaileyH., LewE.D., BurrolaP.G., CallawayP., ZagórskaA., RothlinC.V., NimmerjahnA., and LemkeG. (2016). TAM receptors regulate multiple features of microglial physiology. Nature, 532, 240–244.
31.
Sheffler-CollinsS.I., and DalvaM.B. (2012). EphBs: an integral link between synaptic function and synaptopathies. Trends Neurosci. 35, 293–304.
32.
GuillemotF., and ZimmerC. (2011). From cradle to grave: the multiple roles of fibroblast growth factors in neural development. Neuron, 71, 574–588.
33.
SuE.J., FredrikssonL., KanzawaM., MooreS., FolestadE., StevensonT.K., NilssonI., SashindranathM., SchielkeG.P., WarnockM., RagsdaleM., MannK., LawrenceA.L., MedcalfR.L., ErikssonU., MurphyG.G., and LawrenceD.A. (2015). Imatinib treatment reduces brain injury in a murine model of traumatic brain injury. Front. Cell. Neurosci, 9, 385.
34.
GurnikS., DevrajK., MacasJ., YamajiM., StarkeJ., ScholzA., SommerK., Di TacchioM., VutukuriR., BeckH., MittelbronnM., FoerchC., PfeilschifterW., LiebnerS., PetersK.G., PlateK.H., and ReissY. (2016). Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling. Acta Neuropathol. 31, 753–773.
35.
BeanJ.C., LinT.W., SathyamurthyA., LiuF., YinD.M., XiongW.C., and MeiL. (2014). Genetic labeling reveals novel cellular targets of schizophrenia susceptibility gene: distribution of GABA and non-GABA ErbB4-positive cells in adult mouse brain. J. Neurosci., 34, 13549–13566.
36.
FazzariP., PaternainA.V., ValienteM., PlaR., LujánR., LloydK., LermaJ., MarínO., and RicoB. (2010). Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature, 464, 1376–1380.
37.
NeddensJ., FishK.N., TricoireL., VullhorstD., ShamirA., ChungW., LewisD.A., McBainC.J., and BuonannoA. (2011). Conserved interneuron-specific ErbB4 expression in frontal cortex of rodents, monkeys, and humans: implications for schizophrenia. Biol. Psychiatry, 70, 636–645.
38.
VullhorstD., MitchellR.M., KeatingC., RoychowdhuryS., KaravanovaI., Tao-ChengJ.H., and BuonannoA. (2015). A negative feedback loop controls NMDA receptor function in cortical interneurons via neuregulin 2/ErbB4 signalling. Nat. Commun., 6, 7222.
39.
WenL., LuY.S., ZhuX.H., LiX.M., WooR.S., ChenY.J., YinD.M., LaiC., TerryA.V., VazdarjanovaA., and XiongW.C. (2010). Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proc. Natl. Acad Sci. U. S. A., 107, 1211–1216.
40.
YinD.M., SunX.D., BeanJ.C., LinT.W., SathyamurthyA., XiongW.C., GaoT.M., ChenY.J., and MeiL. (2013). Regulation of spine formation by ErbB4 in PV-positive interneurons. J. Neurosci., 33, 19295–19303.
41.
AtallahB.V., BrunsW., CarandiniM., and ScanzianiM. (2012). Parvalbumin-expressing interneurons linearly transform cortical responses to visual stimuli. Neuron, 73, 159–170.
42.
JacobiN., SeeboeckR., HofmannE., and EgerA. (2017). ErbB family signalling: a paradigm for oncogene addiction and personalized oncology. Cancers (Basel), 9, E33.
43.
FlierlM.A., StahelP.F., BeauchampK.M., MorganS.J., SmithW.R., and ShohamiE. (2009). Mouse closed head injury model induced by a weight-drop device. Nat. Protoc.4, 1328–1337.
44.
LuongT.N., CarlisleH.J., SouthwellA., and PattersonP.H. (2011). Assessment of motor balance and coordination in mice using the balance beam. J. Vis. Exp., 10, 2376.
45.
ZimprichA., GarrettL., DeussingJ.M., WotjakC.T., FuchsH., Gailus-DurnerV., de AngelisM.H., WurstW., and HölterS.M. (2014). A robust and reliable non-invasive test for stress responsivity in mice. Front. Behav. Neurosci., 8, 125.
46.
SaxenaS., RoselliF., SinghK., LeptienK., JulienJ.P., Gros-LouisF., and CaroniP. (2013). Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron, 80, 80–96.
47.
KarunakaranS., ChowdhuryA., DonatoF., QuairiauxC., MichelC.M., and CaroniP. (2016). PV plasticity sustained through D1/5 dopamine signaling required for long-term memory consolidation. Nat. Neurosci., 19, 454–464.
48.
MagnusC.J., LeeP.H., AtasoyD., SuH.H., LoogerL.L., and SternsonS.M. (2011). Chemical and genetic engineering of selective ion channel-ligand interactions. Science, 333, 1292–1296.
49.
SchwarzkopfT.M., HornT., LangD., and KleinJ. (2013). Blood gases and energy metabolites in mouse blood before and after cerebral ischemia: the effects of anesthetics. Exp. Biol. Med. (Maywood) 238, 84–89.
50.
PapaL., BrophyG.M., WelchR.D., LewisL.M., BragaC.F., TanC.N., AmeliN.J., LopezM.A., HaeusslerC.A., Mendez-GiordanoD.I, SilvestriS., GiordanoP., WeberK.D., Hill-PryorC., and HackD.C. (2016). Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurol. 73, 551–560.
51.
HuangX.J., GlushakovaO., MondelloS., VanK., HayesR.L., and LyethB.G. (2015). Acute temporal profiles of serum levels of UCH-L1 and GFAP and relationships to neuronal and astroglial pathology following traumatic brain injury in rats. J. Neurotrauma, 32, 1179–1189.
52.
GereckeK.M., WyssJ.M., KaravanovaI., BuonannoA., and CarrollS.L. (2001). ErbB transmembrane tyrosine kinase receptors are differentially expressed throughout the adult rat central nervous system. J. Comp. Neurol., 433, 86–100.
53.
ThompsonM., LauderdaleS., WebsterM.J., ChongV.Z., McClintockB., SaundersR., and WeickertC.S. (2007). Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain. Brain Res. 30, 95–109.
54.
PolliJ.W., HumphreysJ.E., HarmonK.A., CastellinoS., O'MaraM.J., OlsonK.L., John-WilliamsL.S., KochK.M., and Serabjit-SinghC.J. (2008). The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab. Dispos., 36, 695–701.
55.
HudachekS.F., and GustafsonD.L. (2013). Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans. J. Pharmacokinet. Pharmacodyn., 40, 157–176.
56.
QiaoL., ChoiS., CaseA., GainerT.G., SeybK., GlicksmanM.A., LoD.C., SteinR.L., and CunyG.D. (2009). Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett., 19, 6122–6126.
57.
FlajoletM., WangZ., FutterM., ShenW., NuangchamnongN., BendorJ., WallachI., NairnA.C., SurmeierD.J., and GreengardP. (2008). FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat. Neurosci., 11, 1402–1409.
58.
ThundyilJ., ManzaneroS., PavlovskiD., CullyT.R., LokK.Z., WidiapradjaA., ChunduriP., JoD.G., NaruseC., AsanoM., LaunikonisB.S., SobeyC.G., CoulthardM.G., and ArumugamT.V. (2013). Evidence that the EphA2 receptor exacerbates ischemic brain injury. PloS One, 8, e53528.
59.
AkimotoM., BabaA., Ikeda-MatsuoY., YamadaM.K., ItamuraR., NishiyamaN., IkegayaY., and MatsukiN. (2004). Hepatocyte growth factor as an enhancer of NMDA currents and synaptic plasticity in the hippocampus. Neuroscience, 128, 155–162.
60.
NoltM.J., LinY., HruskaM., MurphyJ., Sheffler-ColinsS.I., KayserM.S., PasserJ., BennettM.V., ZukinR.S., and DalvaM.B. (2011). EphB controls NMDA receptor function and synaptic targeting in a subunit-specific manner. Neuroscience, 31, 5353–5364.
61.
KriebelM., MetzgerJ., TrinksS., ChughD., HarveyR.J., HarveyK., and VolkmerH. (2011). The cell adhesion molecule neurofascin stabilizes axo-axonic GABAergic terminals at the axon initial segment. J. Biol. Chem., 286, 24385–24393.
62.
WuchterJ., BeuterS., TreindlF., HerrmannT., ZeckG., TemplinM.F., and VolkmerH. (2012). A comprehensive small interfering RNA screen identifies signaling pathways required for gephyrin clustering. J. Neurosci., 32, 14821–14834.
63.
MeiL., and XiongW.C. (2008). Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci., 9, 437–452.
64.
GuanY.F., WuC.Y., FangY.Y., ZengY.N., LuoZ.Y., LiS.J., LiX.W., ZhuX.H., MeiL., and GaoT.M. (2015). Neuregulin 1 protects against ischemic brain injury via ErbB4 receptors by increasing GABAergic transmission. Neuroscience, 307, 151–159.
65.
ZhangH., ZhangL., ZhouD., HeX., WangD., PanH., ZhangX., MeiY., QianQ., ZhengT., JonesF.E., and SunB. (2017). Ablating ErbB4 in PV neurons attenuates synaptic and cognitive deficits in an animal model of Alzheimer's disease. Neurobiol. Dis., 106, 171–180.
66.
LuY., SunX.D., HouF.Q., BiL.L., YinD.M., LiuF., ChenY.J., BeanJ.C., JiaoH.F., LiuX., LiB.M., XiongW.C., GaoT.M., and MeiL. (2014). Maintenance of GABAergic activity by neuregulin 1-ErbB4 in amygdala for fear memory. Neuron, 84, 835–846.
67.
TamuraH., KawataM., HamaguchiS., IshikawaY., and ShiosakaS. (2012). Processing of neuregulin-1 by neuropsin regulates GABAergic neuron to control neural plasticity of the mouse hippocampus. J. Neurosci., 32, 12657–12672.
68.
IwakuraY., WangR., InamuraN., ArakiK., HigashiyamaS., TakeiN., and NawaH. (2017). Glutamate-dependent ectodomain shedding of neuregulin-1 type II precursors in rat forebrain neurons. PLoS One, 12, e0174780.
TanG.H., LiuY.Y., HuX.L., YinD.M., MeiL., and XiongZ.Q. (2011). Neuregulin 1 represses limbic epileptogenesis through ErbB4 in parvalbumin-expressing interneurons. Nat. Neurosci., 15, 258–266.
71.
CarronS.F., AlwisD.S., and RajanR. (2016). Traumatic brain injury and neuronal functionality changes in sensory cortex. Front. Syst. Neurosci., 10, 47.
72.
AlwisD.S., YanE.B., Morganti-KossmannM.C., and RajanR. (2012). Sensory cortex underpinnings of traumatic brain injury deficits. PLoS One, 7, e52169.
73.
JohnstoneV.P., YanE.B., Alwi,. D.S., and RajanR. (2013). Cortical hypoexcitation defines neuronal responses in the immediate aftermath of traumatic brain injury. PloS One, 8, e63454.
74.
AllittB.J., IvaP., YanE.B., and RajanR. (2016). Hypo-excitation across all cortical laminae defines intermediate stages of cortical neuronal dysfunction in diffuse traumatic brain injury. Neuroscience, 334, 290–308.
75.
JohnstoneV.P., ShultzS.R., YanE.B., O'BrienT.J., and RajanR. (2014). The acute phase of mild traumatic brain injury is characterized by a distance-dependent neuronal hypoactivity. J. Neurotrauma, 31, 1881–1895.
76.
BadingH. (2013). Nuclear calcium signalling in the regulation of brain function. Nat. Rev. Neurosci., 14, 593–608.
77.
RoselliF., and CaroniP. (2015). From intrinsic firing properties to selective neuronal vulnerability in neurodegenerative diseases. Neuron, 85, 901–910.
78.
ZhangS.J., BuchthalB., LauD., HayerS., DickO., SchwaningerM., VeltkampR., ZouM., WeissU., and BadingH. (2011). A signaling cascade of nuclear calcium-CREB-ATF3 activated by synaptic NMDA receptors defines a gene repression module that protects against extrasynaptic NMDA receptor-induced neuronal cell death and ischemic brain damage. J. Neurosci., 31, 4978–4990.
79.
ZhangS.J., ZouM., LuL., LauD., DitzelD.A., Delucinge-VivierC., AsoY., DescombesP., and BadingH. (2009). Nuclear calcium signaling controls expression of a large gene pool: identification of a gene program for acquired neuroprotection induced by synaptic activity. PLoS Genet, 5, e1000604.
80.
HendryJ.M., Alvarez-VeronesiM.C., PlachetaE., ZhangJ.J., GordonT., and BorschelG.H. (2016). ErbB2 blockade with Herceptin (trastuzumab) enhances peripheral nerve regeneration after repair of acute or chronic peripheral nerve injury. Ann. Neurol., 80, 112–126.
81.
BoerboomA., DionV., ChariotA., and FranzenR. (2017). Molecular mechanisms involved in Schwann cell plasticity. Front. Mol. Neurosci., 10, 38.
82.
BlasioleB., BayrH., VagniV.A., Janesko-FeldmanK., CheikhiA., WisniewskiS.R., LongJ.B., AtkinsJ., KaganV., and KochanekP.M. (2013). Effect of hyperoxia on resuscitation of experimental combined traumatic brain injury and hemorrhagic shock in mice. Anesthesiology, 118, 649–663.
83.
KalsotraA., TurmanC.M., DashP.K., and StrobelH.W. (2003). Differential effects of traumatic brain injury on the cytochrome p450 system: a perspective into hepatic and renal drug metabolism. J. Neurotrauma, 20, 1339–1350.
84.
NizamutdinovD., DeMorrowS., McMillinM., KainJ., MukherjeeS., ZeitouniS., FramptonG., BrickerP.C., HurstJ., and ShapiroL.A. (2017). Hepatic alterations are accompanied by changes to bile acid transporter-expressing neurons in the hypothalamus after traumatic brain injury. Sci. Rep., 7, 40112.
85.
BoucherB.A., and HanesS.D. (1998). Pharmacokinetic alterations after severe head injury. Clinical relevance. Clin. Pharmacokinet., 35, 209–221.
86.
YuanX.Q., WadeC.E., ProughD.S., and DeWittD.S. (1990). Traumatic brain injury creates biphasic systemic hemodynamic and organ blood flow responses in rats. J. Neurotrauma, 7, 141–153.
87.
AfsharM., NetzerG., Salisbury-AfsharE., MurthiS., and SmithG.S. (2016). Injured patients with very high blood alcohol concentrations. Injury, 47, 83–88.
88.
PolliJ.W., HumphreysJ.E., HarmonK.A., CastellinoS., O'maraM.J., OlsonK.L., John-WilliamsL.S., KochK.M., and Serabjit-SinghC.J. (2008). The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl) oxy] phenyl}-6-[5-({[2-(methylsulfonyl) ethyl] amino} methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab. Dispos., 36, 695–701.
89.
MorikawaA., PeereboomD.M., ThorsheimH.R., SamalaR., BalyanR., MurphyC.G., LockmanP.R., SimmonsA., WeilR.J., TabarV., and SteegP.S. (2014). Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-oncology, 17, 289–295.
90.
Sysa-ShahP., TocchettiC.G., GuptaM., RainerP.P., ShenX., KangB.H., BelmonteF., LiJ., XuY., GuoX., and BedjaD. (2015). Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways. Cardiovasc. Res., 109, 358–373.
91.
KedrinD., WyckoffJ., BoimelP.J., ConiglioS.J., HynesN.E., ArteagaC.L., and SegallJ.E. (2009). ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clin. Cancer Res., 15, 3733–3739.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
